In the News
August 19, 2022: Emtora Awarded $16.9M Grant from Cancer Prevention & Research Institute of Texas
February 4, 2020: Emtora Presents Phase Ib Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
August 30, 2019: Texas’ Cancer-Fighting Agency Invests Millions in San Antonio Research
August 27, 2019: SA Biotech's CPRIT Grant Drawing More Investor Interest
August 22, 2019: Emtora Awarded $3M in Texas Cancer Research Funding
May 1, 2019: Emtora Obtains Major Federal Drug Designation
April 30, 2019: Emtora Turns Sights on Rare Genetic Disease, New Funding
March 22, 2019: Local Biotech Companies Work to Navigate Maze to Market
March 13, 2019: Emtora Biosciences CEO Talks New Name, Focus, and Finish Line
February 28, 2019: Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO
February 26, 2019: San Antonio Biotech Changing its Name and CEO
February 26, 2019: Rapamycin Holdings Changes Name to Emtora Biosciences, Hires New CEO
November 1, 2018: SA Drug Development Company Reaches Major Milestone
May 9, 2018: Rapamycin Holdings Plans Tests of eRapa for Prostate Cancer
October 17, 2017: San Antonio Drug Developer Obtains Key Patent Approval in Path to Market
August 7, 2017: New Rapamycin CEO Hired to Handle Funding, FDA Inflection Points
April 1, 2016: Drug Designed in San Antonio Fights Age-Related Diseases
Copyright © 2020 Emtora Biosciences - All Rights Reserved.
Powered by GoDaddy